Cargando…
The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema
INTRODUCTION: Lymphedema can be a debilitating condition, causing a great decrease in a person’s quality of life (QoL). Treatment with lymphaticovenular anastomosis (LVA), in which an anastomosis is created between the lymphatic and venous system, may attenuate lymphedema symptoms and reduce swellin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543202/ https://www.ncbi.nlm.nih.gov/pubmed/28608029 http://dx.doi.org/10.1007/s10549-017-4335-0 |
_version_ | 1783255111259127808 |
---|---|
author | Winters, H. Tielemans, H. J. P. Hameeteman, M. Paulus, V. A. A. Beurskens, C. H. Slater, N. J. Ulrich, D. J. O. |
author_facet | Winters, H. Tielemans, H. J. P. Hameeteman, M. Paulus, V. A. A. Beurskens, C. H. Slater, N. J. Ulrich, D. J. O. |
author_sort | Winters, H. |
collection | PubMed |
description | INTRODUCTION: Lymphedema can be a debilitating condition, causing a great decrease in a person’s quality of life (QoL). Treatment with lymphaticovenular anastomosis (LVA), in which an anastomosis is created between the lymphatic and venous system, may attenuate lymphedema symptoms and reduce swelling. In this study, we share the results using LVA to treat breast cancer-related lymphedema (BCRL) at our institution. MATERIALS AND METHODS: Patients were eligible for inclusion if they suffered from unilateral BCRL, if functional lymphatics were available, if compression therapy was used for at least 6 months, and if the follow-up was 12 months at minimum. Lymph vessel functionality was assessed preoperatively using indocyanine green (ICG). During surgery, 1–3 anastomoses were created and shunt patency was confirmed using ICG. Arm volumes were measured before surgery and at 6- and 12-month follow-up. QoL was measured before surgery and at 6-month follow-up. Arm volume differences between the healthy arm and affected arm were compared between the time points. RESULTS: Twenty-nine consecutive female patients with unilateral BCRL were included. The preoperative mean difference in arm volumes was 701 ± 435 ml (36.9%). This was reduced to 496 ± 302 ml (24.7%) at 6-month follow-up (p = 0.00). At 12-month follow-up, the mean difference in arm volume was 467 ± 303 ml (23.5%) (p = 0.02). The overall perceived QoL was increased from 5.8 ± 1.1 to 7.4 ± 0.7 (p = 0.00). The functionality score decreased from 2.2 to 1.8 (p = 0.00), the appearance score decreased from 2.6 to 1.9 (p = 0.00), the symptoms score decreased from 2.8 to 1.8 (p = 0.00), and the mood score decreased from 2.7 to 1.5 (p = 0.00). Fifteen patients (53.6%) were able to discontinue the use of compression garment. CONCLUSION: Treatment with LVAs is effective in reducing arm volume difference in patients suffering from BCRL. Although no complete reduction of the edema was achieved at 12-month follow-up, the procedure significantly increased the patients’ QoL. |
format | Online Article Text |
id | pubmed-5543202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-55432022017-08-17 The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema Winters, H. Tielemans, H. J. P. Hameeteman, M. Paulus, V. A. A. Beurskens, C. H. Slater, N. J. Ulrich, D. J. O. Breast Cancer Res Treat Clinical Trial INTRODUCTION: Lymphedema can be a debilitating condition, causing a great decrease in a person’s quality of life (QoL). Treatment with lymphaticovenular anastomosis (LVA), in which an anastomosis is created between the lymphatic and venous system, may attenuate lymphedema symptoms and reduce swelling. In this study, we share the results using LVA to treat breast cancer-related lymphedema (BCRL) at our institution. MATERIALS AND METHODS: Patients were eligible for inclusion if they suffered from unilateral BCRL, if functional lymphatics were available, if compression therapy was used for at least 6 months, and if the follow-up was 12 months at minimum. Lymph vessel functionality was assessed preoperatively using indocyanine green (ICG). During surgery, 1–3 anastomoses were created and shunt patency was confirmed using ICG. Arm volumes were measured before surgery and at 6- and 12-month follow-up. QoL was measured before surgery and at 6-month follow-up. Arm volume differences between the healthy arm and affected arm were compared between the time points. RESULTS: Twenty-nine consecutive female patients with unilateral BCRL were included. The preoperative mean difference in arm volumes was 701 ± 435 ml (36.9%). This was reduced to 496 ± 302 ml (24.7%) at 6-month follow-up (p = 0.00). At 12-month follow-up, the mean difference in arm volume was 467 ± 303 ml (23.5%) (p = 0.02). The overall perceived QoL was increased from 5.8 ± 1.1 to 7.4 ± 0.7 (p = 0.00). The functionality score decreased from 2.2 to 1.8 (p = 0.00), the appearance score decreased from 2.6 to 1.9 (p = 0.00), the symptoms score decreased from 2.8 to 1.8 (p = 0.00), and the mood score decreased from 2.7 to 1.5 (p = 0.00). Fifteen patients (53.6%) were able to discontinue the use of compression garment. CONCLUSION: Treatment with LVAs is effective in reducing arm volume difference in patients suffering from BCRL. Although no complete reduction of the edema was achieved at 12-month follow-up, the procedure significantly increased the patients’ QoL. Springer US 2017-06-12 2017 /pmc/articles/PMC5543202/ /pubmed/28608029 http://dx.doi.org/10.1007/s10549-017-4335-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Winters, H. Tielemans, H. J. P. Hameeteman, M. Paulus, V. A. A. Beurskens, C. H. Slater, N. J. Ulrich, D. J. O. The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
title | The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
title_full | The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
title_fullStr | The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
title_full_unstemmed | The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
title_short | The efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
title_sort | efficacy of lymphaticovenular anastomosis in breast cancer-related lymphedema |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543202/ https://www.ncbi.nlm.nih.gov/pubmed/28608029 http://dx.doi.org/10.1007/s10549-017-4335-0 |
work_keys_str_mv | AT wintersh theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT tielemanshjp theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT hameetemanm theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT paulusvaa theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT beurskensch theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT slaternj theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT ulrichdjo theefficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT wintersh efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT tielemanshjp efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT hameetemanm efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT paulusvaa efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT beurskensch efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT slaternj efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema AT ulrichdjo efficacyoflymphaticovenularanastomosisinbreastcancerrelatedlymphedema |